Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer multidrug resistance

Nature Biotechnology volume 18, pages IT18–IT20 (2000)Cite this article

Progress in understanding the molecular basis of drug resistance in cancer promises more effective treatments.

Multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy. It affects patients with a variety of blood cancers and solid tumors, including breast, ovarian, lung, and lower gastrointestinal tract cancers. Tumors usually consist of mixed populations of malignant cells, some of which are drug-sensitive while others are drug-resistant. Chemotherapy kills drug-sensitive cells, but leaves behind a higher proportion of drug-resistant cells. As the tumor begins to grow again, chemotherapy may fail because the remaining tumor cells are now resistant.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rennick, B.R. et al. J. Pharmacol. Exp. Ther. 91, 210– 217 (1947).

    CAS  PubMed  Google Scholar 

  2. Juliano, R.L. & Ling, V. Biochim. Biophys. Acta 455, 152–162 (1976).

    Article  CAS  Google Scholar 

  3. Riordan, J.R. & Ling, V. J. Biol. Chem. 254, 12701–12705 (1979).

    CAS  PubMed  Google Scholar 

  4. Debenham, P.G. et al. Mol. Cell Biol. 2, 881–889 (1982).

    Article  CAS  Google Scholar 

  5. Riordan, J.R. et al. Nature 316, 817–819 ( 1985).

    Article  Google Scholar 

  6. Chen, C.J. et al. Cell 47, 381–389 ( 1986).

    Article  CAS  Google Scholar 

  7. Cole, S.P. et al. Science 258, 1650–1654 ( 1992).

    Article  CAS  Google Scholar 

  8. Bellamy, W.T. Ann. Rev. Pharmacol. Toxixol. 36, 161– 183 (1996).

    Article  CAS  Google Scholar 

  9. Kolaczkowski, M. et al. Microb. Drug. Resist. 4, 143– 148 (1998).

    Article  CAS  Google Scholar 

  10. Braybrooke, J.P. et al. Cancer Chemother. Pharmacol. 46, 27– 34 (2000).

    Article  CAS  Google Scholar 

  11. Nakamura, M. et al. Anticancer Res. 20, 1921– 1925 (2000).

    CAS  PubMed  Google Scholar 

  12. Pierre, A. et al. Cancer Chemother. Pharmacol. 42, 454– 460 (1998).

    Article  CAS  Google Scholar 

  13. Oshika, Y. et al. Mod. Pathol. 11, 1059–1063 (1998).

    CAS  PubMed  Google Scholar 

  14. Bakos, E. et al. J. Biol. Chem. 273, 32167–32175 (1998).

    Article  CAS  Google Scholar 

  15. Weinstein, J.N. et al. Science 275, 343 ( 1998).

    Article  Google Scholar 

  16. Marthinet, E. et al. Gene Ther. 7, 1224–1233 (2000).

    Article  CAS  Google Scholar 

  17. Bartsevich, V.V. & Juliano, R.L. Mol. Pharmacol. 58, 1–10 (2000 ).

    Article  CAS  Google Scholar 

  18. Tiberghien, F. et al. J. Med. Chem. 43, 2547– 2556 (2000).

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cancer multidrug resistance. Nat Biotechnol 18 (Suppl 10), IT18–IT20 (2000). https://doi.org/10.1038/80051

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/80051

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing